2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐 | 1280210-80-1

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐
• 中文别名: 奥格列汀中间体3；MK3102中间体3；MK-3102中间体3；2-(甲基磺酰基)-2,4,5,6-四氢吡咯并[3,4-C]吡唑苯磺酸盐；奥格列汀中间体2；(OMARIGLIPTIN)MK-3102中间体3；MK-312中间体3；2-(甲基磺酰基)-2,45,6-四氢吡咯并3,4-c]吡唑
• 英文名称: 2-(methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-5-ium benzenesulfonate
• 英文别名: benzenesulfonate;2-methylsulfonyl-5,6-dihydro-4H-pyrrolo[3,4-c]pyrazol-5-ium
• CAS: 1280210-80-1
• 化学式: C₆H₆O₃S*C₆H₉N₃O₂S
• 分子量: 345.4
• InChiKey: PKMDOTHXIGJTKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.23
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥环境中保存。

反应信息

• 作为反应物：
  描述：

  2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐 在 N,N-二甲基乙酰胺 、 三乙酰氧基硼氢化钠 、 苯磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 生成 奥格列汀
  参考文献：
  名称：

  [EN] NOVEL CRYSTALLINE FORMS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
  [FR] NOUVELLES FORMES CRISTALLINES D'UN INHIBITEUR DE PEPTIDASE-IV

  摘要：

  (2R,3S,5R)-2-(2,5-二氟苯基)-5-[2-(甲磺酰基)-2,6-二氢吡咯并[3,4-c]吡唑-5(4H)-基]四氢-2H-吡喃-3-胺的新型晶体形态是二肽基肽酶-IV的有效抑制剂，可用于治疗非胰岛素依赖性（2型）糖尿病。本发明还涉及含有这些新型形态的制药组合物，制备这些形态及其制药组合物的方法以及它们用于治疗2型糖尿病的用途。

  公开号：

  WO2013003249A1
• 作为产物：
  描述：

  N-[(2R,3S)-2-(2,5-二氟苯基)四氢-5-氧代-2H-吡喃-3-基]氨基甲酸叔丁酯 以79的产率得到2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐
  参考文献：
  名称：

  J. Label. Compd. Radiopharm. 1995, 36, 701-712

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-[(2R,3S)-2-(2,5-二氟苯基)四氢-5-氧代-2H-吡喃-3-基]氨基甲酸叔丁酯 、 2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐 在 2,4,5,6-四氢-2-(甲基磺酰基)吡咯并[3,4-C]吡唑苯磺酸盐 作用下， 以94的产率得到tert-butyl N-[2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-yl]carbamate
  参考文献：
  名称：

  J. Med. Chem. 2014, 57, 3205-3212

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOPIPÉRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011037793A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ΪV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基哌啶，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] SUBSTITUTED SEVEN-MEMBERED HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS À SEPT CHAÎNONS EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL-PEPTIDASE IV POUR LE TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011146358A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式（I）的新型氨基取代的七元杂环化合物，这些化合物是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] SUBSTITUTED AMINOTETRAHYDROTHIOPYRANS AND DERIVATIVES THEREOF AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOTÉTRAHYDROTHIOPYRANES SUBSTITUÉS ET DÉRIVÉS DE CEUX-CI UTILISÉS EN TANT QU'INHIBITEURS DE LA DIPEPTIDYLPEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011103256A1

  公开（公告）日：2011-08-25

  The present invention is directed to novel substituted aminotetrahydrothiopyrans and derivatives thereof of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代氨基四氢硫代吡喃及其衍生物，其化学结构式为(I)，这些化合物是二肽基肽酶-IV酶的抑制剂，对于治疗或预防二肽基肽酶-IV酶参与的疾病非常有用，例如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• A one-pot synthesis of omarigliptin and its analogues through stabilized <i>beta</i>-amino ketone intermediate
  作者：You Li、Tongchao Liu、Chungang Li、Bing Xiong、Dongmei Zhao、Maosheng Cheng、Guohua Chen、Jingkang Shen、Yue-Lei Chen

  DOI：10.1080/00397911.2016.1265129

  日期：2017.2.16

  ABSTRACT We have discovered a unique stabilization condition for beta-amino ketone 7. With compound 7 as an unprecedented intermediate, omarigliptin 1 could be prepared in a highly efficient one-pot procedure with good yield. Also with this intermediate 7, some analogues of omarigliptin 1 were readily prepared for the first time. GRAPHICAL ABSTRACT

  摘要我们发现了β-氨基酮7 的独特稳定条件。将化合物7 作为一种前所未有的中间体，奥格列汀1 可以以高产率的高效一锅法制备。同样使用中间体 7，首次很容易地制备了奥格列汀 1 的一些类似物。图形概要
• [EN] TREATING DIABETES WITH DIPEPTIDYL PEPTIDASE-IV INHIBITORS<br/>[FR] TRAITEMENT DU DIABÈTE PAR ADMINISTRATION D'INHIBITEURS DE DIPEPTIDYL PEPTIDASE-IV
  申请人：MERCK SHARP & DOHME

  公开号：WO2014018350A1

  公开（公告）日：2014-01-30

  The present invention is directed to novel substituted dihydropyrrolopyrazoles of structural Formula I which are inhibitors of the dipeptidyl peptidase-N enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase IV enzyme is involved.

  本发明涉及一种新型结构式I的取代二氢吡咯吡唑化合物，这些化合物是二肽基肽酶-N酶的抑制剂，并且在治疗或预防涉及二肽基肽酶-IV酶的疾病方面具有用处，例如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及二肽基肽酶IV酶的疾病方面的用途。